{"transactions":[{"id":4615497,"issuer":{"id":4686,"kind":"organization","name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","symbol":"KMTS"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-11T00:43:30.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":7217,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities represent restricted stock units (\"RSUs\") which each entitle the Reporting Person to receive one common share of the Issuer.  The RSUs will vest on September 9, 2027, subject to the Reporting Person's continued service through such date."}],"balance_after":14236,"source":{"system":"sec-edgar","filing":"0000950130-26-000223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877184/000095013026000223/ownership.xml","form_type":"4"}},{"id":4615496,"issuer":{"id":4686,"kind":"organization","name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","symbol":"KMTS"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-11T00:43:30.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":3890,"price":25.178,"value":97942.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4240. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range."}],"balance_after":7019,"source":{"system":"sec-edgar","filing":"0000950130-26-000223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877184/000095013026000223/ownership.xml","form_type":"4"}},{"id":1045979,"issuer":{"id":4686,"kind":"organization","name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","symbol":"KMTS"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-09-08T21:27:57.000Z","date":"2025-09-04","kind":"grant","planned":false,"acquired":true,"shares":10909,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent restricted stock units (\"RSUs\") which each entitle the Reporting Person to receive one common share of the Issuer.  The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent restricted stock units (\"RSUs\") which each entitle the Reporting Person to receive one common share of the Issuer.  The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date."}],"balance_after":10909,"source":{"system":"sec-edgar","filing":"0000950170-25-113627","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877184/000095017025113627/ownership.xml","form_type":"4"}},{"id":1500037,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T20:59:40.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":28650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date."}],"balance_after":28650,"derivative":{"exercise_price":0.82,"expiration_date":"2034-05-22","underlying":"Class A Common Stock","underlying_shares":28650},"source":{"system":"sec-edgar","filing":"0000950170-24-065323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1380106/000095017024065323/ownership.xml","form_type":"4"}},{"id":1500036,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-05-28T20:59:40.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":14300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units (\"RSUs\") that vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date."}],"balance_after":14300,"source":{"system":"sec-edgar","filing":"0000950170-24-065323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380106/000095017024065323/ownership.xml","form_type":"4"}},{"id":1877624,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T17:04:48.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":13774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":13774,"derivative":{"exercise_price":32.27,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":13774},"source":{"system":"sec-edgar","filing":"0000899243-23-013903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924323013903/doc4.xml","form_type":"4"}},{"id":1877623,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T17:04:48.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":4648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":10572,"source":{"system":"sec-edgar","filing":"0000899243-23-013903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924323013903/doc4.xml","form_type":"4"}},{"id":1902291,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-06T00:41:45.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.8705,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-23-012409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380106/000089924323012409/doc4.xml","form_type":"4"}},{"id":1944108,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-20T17:00:14.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":1750000,"price":28.5,"value":49875000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the general partner of BC SW, LP. Mr. Schwartz is a Partner of BCLSI. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3081307,"source":{"system":"sec-edgar","filing":"0000899243-23-009117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924323009117/doc4.xml","form_type":"4"}},{"id":2235535,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T00:21:42.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.5,"expiration_date":"2032-05-22","underlying":"Class A Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-22-022034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380106/000089924322022034/doc4.xml","form_type":"4"}},{"id":2261301,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T18:23:23.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":15318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The options will vest in full on the earlier of (1) May 19, 2023 and (2) the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date."}],"balance_after":15318,"derivative":{"exercise_price":35.42,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":15318},"source":{"system":"sec-edgar","filing":"0000899243-22-019105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924322019105/doc4.xml","form_type":"4"}},{"id":2261300,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-20T18:23:23.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":4818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date."}],"balance_after":5924,"source":{"system":"sec-edgar","filing":"0000899243-22-019105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924322019105/doc4.xml","form_type":"4"}},{"id":2605004,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-13T00:38:04.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1000000,"price":70.25,"value":70250000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BC SW, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":4831307,"source":{"system":"sec-edgar","filing":"0000899243-21-032893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924321032893/doc4.xml","form_type":"4"}},{"id":2628212,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C1 Preferred Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":false,"shares":6672819,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1334562},"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628211,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B1 Preferred Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":false,"shares":35000001,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":6999998},"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628210,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"purchase","acquired":true,"shares":100000,"price":20,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents 90,714 and 9,286 shares of the Issuer's Class A Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":8434560,"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628209,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":true,"shares":1334562,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":8334560,"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2628208,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-21T20:40:41.000Z","date":"2021-07-19","kind":"exercise","acquired":true,"shares":6999998,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":6999998,"source":{"system":"sec-edgar","filing":"0000899243-21-029222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924321029222/doc4.xml","form_type":"4"}},{"id":2631736,"issuer":{"id":6966,"kind":"organization","name":"RAPID MICRO BIOSYSTEMS, INC."},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-16T20:30:13.000Z","date":"2021-07-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021."}],"balance_after":25000,"derivative":{"exercise_price":20,"expiration_date":"2031-07-13","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-028644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380106/000089924321028644/doc4.xml","form_type":"4"}},{"id":2698088,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-24T17:45:03.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":6998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the earlier of (1) May 20, 2022 and (2) the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date."}],"balance_after":6998,"derivative":{"exercise_price":75.94,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":6998},"source":{"system":"sec-edgar","filing":"0000899243-21-020446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924321020446/doc4.xml","form_type":"4"}},{"id":2698087,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T17:45:03.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock award. The restricted stock award will vest in full on the earlier of (1) May 20, 2022 and (2) the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date."}],"balance_after":1106,"source":{"system":"sec-edgar","filing":"0000899243-21-020446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924321020446/doc4.xml","form_type":"4"}},{"id":2794103,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:30:16.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":1450000,"price":71.5,"value":103675000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock held directly by BC SW, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Schwartz is a director of the Issuer."}],"balance_after":5831307,"source":{"system":"sec-edgar","filing":"0000899243-21-011153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924321011153/doc4.xml","form_type":"4"}},{"id":2999318,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-27T21:07:36.000Z","date":"2020-10-26","kind":"purchase","acquired":true,"shares":3333333,"price":3,"value":9999999.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 26, 2020, Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and BCIP Life Sciences Fund, LP (\"BCIPLS and, together with BCLS, the \"Bain Capital Life Sciences Entities\") purchased an aggregate of 3,333,333 shares of Common Stock in an underwritten public offering at a price per share of $3.00. BCLS purchased 3,023,816 of such shares and BCIPLS purchased 309,517 of such shares. Following such purchases, BCLS holds 8,066,113 shares of Common Stock and BCIPLS holds 825,645 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Adam Koppel is a director of the Issuer."}],"balance_after":8891758,"source":{"system":"sec-edgar","filing":"0000899243-20-029321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320029321/doc4.xml","form_type":"4"}},{"id":3000202,"issuer":{"id":145747,"kind":"organization","name":"BCLS Acquisition Corp.","symbol":"BLSA"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares","published_at":"2020-10-26T16:30:12.000Z","date":"2020-10-26","kind":"grant","acquired":true,"shares":487500,"price":10,"value":4875000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased from the Issuer in a private placement by BCLS Acquisition Holdings, LP (the \"Sponsor\") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-249284)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the Sponsor. The Sponsor is controlled by its general partner, BCLS Acquisition Holdings (GP), LLC (the \"General Partner\"), which is governed by a board of managers consisting of three managers. Each manager has one vote, and the approval of a majority of the managers is required to approve an action on behalf of the Sponsor. Jeffrey Schwartz serves on the board of managers of the General Partner. As a result, Mr. Schwartz may be deemed to share beneficial ownership of the shares held by the Sponsor. Mr. Schwartz disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":487500,"source":{"system":"sec-edgar","filing":"0000899243-20-029239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823200/000089924320029239/doc4.xml","form_type":"4"}},{"id":3074856,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":2812543,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":319243},"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074855,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":22222221,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2522385},"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074854,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":400000,"price":17,"value":6800000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents 362,858 and 37,142 shares of the Issuer's Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3241628,"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074853,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":319243,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2841628,"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3074852,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":2,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":3,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":5,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T20:45:58.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":2522385,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock (\"Series C Stock\") and Series D Preferred Stock (\"Series D Stock\") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2522385,"source":{"system":"sec-edgar","filing":"0000899243-20-020554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320020554/doc4.xml","form_type":"4"}},{"id":3136447,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T16:16:02.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":7464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (1) May 20, 2021 or (2) the next annual meeting of stockholders,  subject to continued service to the Issuer on each vesting date."}],"balance_after":7464,"derivative":{"exercise_price":38.03,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":7464},"source":{"system":"sec-edgar","filing":"0000899243-20-013997","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924320013997/doc4.xml","form_type":"4"}},{"id":3286596,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":859573,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":859573},"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286595,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":2825602,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2825602},"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286594,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"purchase","acquired":true,"shares":294117,"price":17,"value":4999989.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents 266,807 and 27,310 shares of Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3979292,"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286593,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":859573,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3685175,"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3286592,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":5,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":6,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T21:26:40.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":2825602,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock (\"Series B Stock\") and Series C Preferred Stock (\"Series C Stock\") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.  The Series B Stock and the Series C Stock each had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. (\"BCLS\") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. (\"BCIPLS\" and, together with BCLS, the \"Bain Capital Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Partners, LP (\"BCLSP\") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2825602,"source":{"system":"sec-edgar","filing":"0000899243-20-003487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924320003487/doc4.xml","form_type":"4"}},{"id":3363085,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-21T21:26:43.000Z","date":"2019-11-19","kind":"sale","acquired":false,"shares":1750000,"price":22.03,"value":38552500.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 19, 2019 Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Capital Life Sciences Entities\") sold 1,582,973 and 167,027 shares of common stock, respectively, pursuant to Rule 144 under the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Koppel is a director of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Partners, LP (\"BC LS P\") is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS.  BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC.  As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":5580237,"source":{"system":"sec-edgar","filing":"0000899243-19-027786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924319027786/doc4.xml","form_type":"4"}},{"id":3409667,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":1053204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1053204},"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409666,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":6078103,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6078103},"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409665,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":150000,"price":18,"value":2700000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":7281307,"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409664,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":1053204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":7131307,"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3409663,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104416,"kind":"organization","name":"BC SW, LP","position":2,"cik":"0001786351","reported_name":"BC SW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":3,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":4,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T23:05:35.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":6078103,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by BC SW, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Jeffrey Schwartz is a director of the Issuer."}],"balance_after":6078103,"source":{"system":"sec-edgar","filing":"0000899243-19-023936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000089924319023936/doc4.xml","form_type":"4"}},{"id":3413477,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-09-16T19:52:12.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":6931142,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1053204,"derivative":{"underlying":"Common Stock","underlying_shares":1053204},"source":{"system":"sec-edgar","filing":"0000899243-19-023677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924319023677/doc4.xml","form_type":"4"}},{"id":3413476,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-09-16T19:52:12.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":40000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":6078103,"derivative":{"underlying":"Common Stock","underlying_shares":6078103},"source":{"system":"sec-edgar","filing":"0000899243-19-023677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924319023677/doc4.xml","form_type":"4"}},{"id":3413475,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":1,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option  (Right to Buy)","published_at":"2019-09-16T19:52:12.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":29983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date."}],"balance_after":29983,"derivative":{"exercise_price":18,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":29983},"source":{"system":"sec-edgar","filing":"0000899243-19-023677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702957/000089924319023677/doc4.xml","form_type":"4"}},{"id":3506435,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:15:40.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":1600000,"price":12.5,"value":20000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 29, 2019, Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Life Sciences Entities\") sold 1,447,289 and 152,711 shares of common stock, respectively, directly to a private investor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Koppel is a director of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Life Sciences Partners, LP (\"BC LS P\") is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC. As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":7330237,"source":{"system":"sec-edgar","filing":"0000899243-19-015281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924319015281/doc4.xml","form_type":"4"}},{"id":3860935,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-07-26T20:27:37.000Z","date":"2018-07-24","kind":"exercise","acquired":false,"shares":235146,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2338968},"source":{"system":"sec-edgar","filing":"0000899243-18-020659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924318020659/doc4.xml","form_type":"4"}},{"id":3860934,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-26T20:27:37.000Z","date":"2018-07-24","kind":"purchase","acquired":true,"shares":500000,"price":15,"value":7500000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On July 24, 2018, the Bain Life Sciences Entities purchased, in aggregate, 500,000 shares of Common Stock of the Issuer at a price of $15 per share, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2838968,"source":{"system":"sec-edgar","filing":"0000899243-18-020659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924318020659/doc4.xml","form_type":"4"}},{"id":3860933,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-26T20:27:37.000Z","date":"2018-07-24","kind":"exercise","acquired":true,"shares":2338968,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the \"Bain Life Sciences Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC (\"BCI LS\"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":2338968,"source":{"system":"sec-edgar","filing":"0000899243-18-020659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924318020659/doc4.xml","form_type":"4"}},{"id":4126562,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T01:30:55.000Z","date":"2017-12-19","kind":"sale","acquired":false,"shares":55229,"price":7.1055,"value":392429.6595,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"On December 19, 2017, BC LS and BCIP LS sold 50,101 and 5,128 shares of common stock, respectively, at a weighted average price of $7.1055.  The shares were sold in multiple transactions at prices ranging from $6.86 to $7.498.  Following such sales, BC LS and BCIP LS held 3,608,127 and 369,326 shares of common stock, respectively."},{"field":"shares","element":"transactionShares","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 19, 2017, BC LS and BCIP LS sold 50,101 and 5,128 shares of common stock, respectively, at a weighted average price of $7.1055.  The shares were sold in multiple transactions at prices ranging from $6.86 to $7.498.  Following such sales, BC LS and BCIP LS held 3,608,127 and 369,326 shares of common stock, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3977453,"source":{"system":"sec-edgar","filing":"0000899243-17-029256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029256/doc4.xml","form_type":"4"}},{"id":4126561,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T01:30:55.000Z","date":"2017-12-19","kind":"sale","acquired":false,"shares":94771,"price":7.6209,"value":722240.3139,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On December 19, 2017, BC LS and BCIP LS sold 85,971 and 8,800 shares of common stock, respectively, at a weighted average price of $7.6209.  The shares were sold in multiple transactions at prices ranging from $7.50 to $8.02.  Following such sales, BC LS and BCIP LS held 3,658,228 and 374,454 shares of common stock, respectively."},{"field":"shares","element":"transactionShares","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On December 19, 2017, BC LS and BCIP LS sold 85,971 and 8,800 shares of common stock, respectively, at a weighted average price of $7.6209.  The shares were sold in multiple transactions at prices ranging from $7.50 to $8.02.  Following such sales, BC LS and BCIP LS held 3,658,228 and 374,454 shares of common stock, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":4032682,"source":{"system":"sec-edgar","filing":"0000899243-17-029256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029256/doc4.xml","form_type":"4"}},{"id":4126560,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T01:30:55.000Z","date":"2017-12-18","kind":"sale","acquired":false,"shares":300000,"price":7.5048,"value":2251440.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On December 18, 2017, BC LS and BCIP LS sold 272,143 and 27,857 shares of common stock, respectively, at a weighted average price of $7.5048.  The shares were sold in multiple transactions at prices ranging from $7.05 to $7.905.  Following such sales, BC LS and BCIP LS held 3,744,199 and 383,254 shares of common stock, respectively."},{"field":"shares","element":"transactionShares","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 18, 2017, BC LS and BCIP LS sold 272,143 and 27,857 shares of common stock, respectively, at a weighted average price of $7.5048.  The shares were sold in multiple transactions at prices ranging from $7.05 to $7.905.  Following such sales, BC LS and BCIP LS held 3,744,199 and 383,254 shares of common stock, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":4127453,"source":{"system":"sec-edgar","filing":"0000899243-17-029256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029256/doc4.xml","form_type":"4"}},{"id":4126559,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T01:30:55.000Z","date":"2017-12-15","kind":"sale","acquired":false,"shares":102882,"price":8.636,"value":888488.952,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On December 15, 2017, BC LS and BCIP LS sold 93,329 and 9,553 shares of common stock, respectively, at a weighted average price of $8.636.  The shares were sold in multiple transactions at prices ranging from $8.50 to $9.045.  Following such sales, BC LS and BCIP LS held 4,016,342 and 411,111 shares of common stock, respectively."},{"field":"shares","element":"transactionShares","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 15, 2017, BC LS and BCIP LS sold 93,329 and 9,553 shares of common stock, respectively, at a weighted average price of $8.636.  The shares were sold in multiple transactions at prices ranging from $8.50 to $9.045.  Following such sales, BC LS and BCIP LS held 4,016,342 and 411,111 shares of common stock, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":4427453,"source":{"system":"sec-edgar","filing":"0000899243-17-029256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029256/doc4.xml","form_type":"4"}},{"id":4126558,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T01:30:55.000Z","date":"2017-12-15","kind":"sale","acquired":false,"shares":719665,"price":8.0179,"value":5770202.0035,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 15, 2017, Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Life Sciences Entities\") sold 652,840 and 66,825 shares of common stock, respectively, at a weighted average price of $8.0179.  The shares were sold in multiple transactions at prices ranging from $7.89 to $8.495.  Following such sales, BC LS and BCIP LS held 4,109,671 and 420,664 shares of common stock, respectively."},{"field":"shares","element":"transactionShares","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 15, 2017, Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Life Sciences Entities\") sold 652,840 and 66,825 shares of common stock, respectively, at a weighted average price of $8.0179.  The shares were sold in multiple transactions at prices ranging from $7.89 to $8.495.  Following such sales, BC LS and BCIP LS held 4,109,671 and 420,664 shares of common stock, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":4530335,"source":{"system":"sec-edgar","filing":"0000899243-17-029256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029256/doc4.xml","form_type":"4"}},{"id":4126574,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Redeemable Convertible Preferred Stock","published_at":"2017-12-19T21:52:08.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":250000,"price":3.19,"value":797500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock.  The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\"  Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price.  The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock.  The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\"  Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price.  The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock.  The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\"  Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price.  The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8454388},"source":{"system":"sec-edgar","filing":"0000899243-17-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029183/doc4.xml","form_type":"4"}},{"id":4126573,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-19T21:52:08.000Z","date":"2017-12-18","kind":"grant","acquired":true,"shares":190849,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock.  The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\"  Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price.  The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On December 18, 2017, each of BC LS and BCIP LS received an additional 172,633 and 18,216 shares of common stock, respectively, from the Issuer representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that each of BC LS and BCIP LS would have been entitled to receive up to and including March 31, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8930237,"source":{"system":"sec-edgar","filing":"0000899243-17-029183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029183/doc4.xml","form_type":"4"}},{"id":4126572,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-19T21:52:08.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":8454388,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock.  The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\"  Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price.  The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8739388,"source":{"system":"sec-edgar","filing":"0000899243-17-029183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029183/doc4.xml","form_type":"4"}},{"id":4126571,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44734,"kind":"organization","name":"Bain Capital Life Sciences Partners, LP","position":2,"cik":"0001703030","reported_name":"Bain Capital Life Sciences Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44735,"kind":"organization","name":"Bain Capital Life Sciences Fund, L.P.","position":3,"cik":"0001687968","reported_name":"Bain Capital Life Sciences Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44736,"kind":"organization","name":"BCIP Life Sciences Associates, LP","position":4,"cik":"0001702921","reported_name":"BCIP Life Sciences Associates, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75682,"kind":"person","name":"Schwartz Jeffrey Lawrence","position":5,"cik":"0001702957","reported_name":"Schwartz Jeffrey Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51911,"kind":"person","name":"Koppel Adam","position":6,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-19T21:52:08.000Z","date":"2017-12-18","kind":"purchase","acquired":true,"shares":285000,"price":7,"value":1995000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2017, Bain Capital Life Sciences Fund, L.P. (\"BC LS\") and BCIP Life Sciences Associates, LP (\"BCIP LS\" and, together with BC LS, the \"Bain Life Sciences Entities\") purchased 257,798 and 27,202 shares of common stock, respectively, in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bain Capital Life Sciences Investors, LLC (\"BCI LS\") is the general partner of Bain Capital Life Sciences Partners, LP (\"BC LS P\"), which is the general partner of BC LS.  As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel.  As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities.  BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":285000,"source":{"system":"sec-edgar","filing":"0000899243-17-029183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687968/000089924317029183/doc4.xml","form_type":"4"}}]}